DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

Julie Krop, Chief Medical Officer of DiaMedica Therapeutics

“Enrollment of the 200th participant brings ReMEDy2 to the prespecified threshold for the trial’s interim analysis”

Julie Krop, Chief Medical Officer of DiaMedica Therapeutics

“We are grateful to the entire DiaMedica team as well as the participants, investigators and clinical sites participating in ReMEDy2 across our global network.”

Julie Krop, Chief Medical Officer of DiaMedica Therapeutics

“The independent DSMB analysis will determine the final size of the trial as we continue evaluating DM199 as a potential new treatment for patients suffering an acute ischemic stroke.”

Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics

“ReMEDy2 was designed with the potential to support registration if successful”

Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics

“The adaptive design provides a disciplined and efficient framework to determine the appropriate final sample size while preserving the opportunity to demonstrate a clinically meaningful treatment effect.”

Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics

“We believe DM199 has the potential to address a substantial unmet need in acute ischemic stroke by improving blood flow to ischemic brain tissue supporting neuronal survival and enabling greater patient recoveries.”